- Future Download
- Posts
- 🧎AI in healthcare
Future Download
A.I., Crypto & Tech Stocks
Future Download: AI in Healthcare - The Next Biotech Boom
This week, we’re diving into AI in healthcare—a sector buzzing with innovation and investment potential. From drug discovery to personalized medicine, AI is reshaping biotech, and investors are taking notice.
Let’s break down what’s happening, why it matters, and how you can get in on the action.
AI in Healthcare: What’s the Buzz?
Artificial intelligence is supercharging healthcare, and the numbers prove it.
AI-driven biotech startups are pulling in massive venture capital—some doubling their valuations in months. Thrive Capital’s recent bet on an AI healthcare firm is just one example, with VC funding in the sector hitting record highs.
Companies like Palantir (PLTR) are using AI to crunch massive datasets, speeding up drug discovery and tailoring treatments to individual patients. Meanwhile, startups are leveraging AI to predict disease risks and optimize hospital operations, making healthcare smarter and faster.
Why It’s Hot: Unlike crypto’s wild swings, healthcare offers stability with high-growth potential. AI is cutting drug development costs (from $2B to under $500M in some cases) and shortening timelines, creating a goldmine for investors betting on the next big biotech breakthrough.
Why Should You Care?
For investors, AI in healthcare is a sweet spot: it’s less volatile than crypto but has unicorn-level upside.
The global healthcare AI market is projected to hit $200B by 2030, driven by demand for personalized medicine and efficient systems. Big players like Google and NVIDIA are in the game, but smaller startups are where the real growth lies—some are already eyeing IPOs. Plus, healthcare stocks tend to weather economic storms better than tech-heavy sectors, making this a solid pick for diversified portfolios.
Risk Alert: High valuations (e.g., Palantir’s 167x forward earnings) mean you need to be picky. Regulatory hurdles and long R&D cycles can also delay returns, so patience is key.
What Can You Do?
Ready to dip your toes in? Here’s how to play the AI healthcare boom without betting the farm:
ETF Picks: Broad Exposure to AI and Biotech
ETFs provide diversified exposure to the AI and biotech sectors, reducing the risk associated with individual stock volatility. These funds are ideal for investors seeking long-term growth with moderate risk.
Expense Ratio: 0.75% (higher than passive ETFs but justified by active management).
Recommended Allocation: 5-10% of a diversified portfolio for growth-oriented investors.
Why Invest?: ARKG offers exposure to cutting-edge innovations with a team of analysts deeply focused on disruptive technologies. It’s suitable for investors with a 5-10 year horizon.
Risks: High volatility due to the speculative nature of biotech startups. Regulatory hurdles and clinical trial failures can impact returns.
Actively managed by ARK Invest, ARKG focuses on companies leveraging AI, genomics, and biotechnology to innovate in healthcare. The fund invests in areas like gene editing (CRISPR), precision medicine, and AI-driven diagnostics.
Since its inception in 2014, ARKG has delivered an average annual return of approximately 15%, though it has experienced significant volatility (e.g., a 30% drawdown in 2022).
Holdings Includes companies like CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), and Invitae (NVTA). About 20% of the portfolio is dedicated to AI-driven biotech firms.
Expense Ratio: 0.68%.
Why Invest?: AIQ balances exposure to established tech companies and emerging AI innovators, making it less volatile than ARKG while still capturing biotech AI trends.
Risks: Less focused on biotech than ARKG, so investors may miss out on pure-play genomic opportunities.
Recommended Allocation: 5-15% of a portfolio, especially for those seeking a mix of AI and broader tech exposure.
AIQ tracks companies involved in AI development, including those with biotech applications, such as AI-powered drug discovery platforms.
Since its launch in 2018, AIQ has achieved an average annual return of ~12%, with lower volatility than ARKG.
Holdings includes tech giants like NVIDIA (NVDA) and IBM (IBM), as well as smaller players like C3.ai (AI) and biotech-adjacent firms like Schrödinger (SDGR).
Stock Picks: High-Risk, High-Reward Opportunities
Individual stocks offer the potential for outsized returns but come with significant risks, including company-specific challenges and market volatility. Below are two standout picks in the AI-biotech space.
Valuation: As of April 2025, PLTR trades at a forward P/E of ~60, reflecting its growth premium.
Why Invest?: Palantir’s ability to secure large-scale government and healthcare contracts positions it as a leader in AI-driven data solutions. Its long-term potential is substantial if it sustains growth.
Risks: High valuation, competition from rivals like Snowflake (SNOW), and reliance on government contracts introduce uncertainty.
Recommended Allocation: 2-5% of a portfolio due to its speculative nature.
Palantir’s AI-driven data analytics platform, Foundry, is increasingly used in healthcare to optimize hospital operations, accelerate drug discovery, and manage patient data for major institutions like the NIH and NHS.
Since its IPO in 2020, PLTR has been highly volatile, with a 50%+ gain in 2023 but a 40% drop in 2022. Analysts project 20-30% annual revenue growth through 2027.
Palantir’s healthcare segment is expanding rapidly, with contracts for AI-powered clinical trial optimization and real-world evidence analysis.
Valuation: Trades at a price-to-sales ratio of ~10, high but typical for early-stage biotech firms.
Why Invest?: Recursion’s AI platform reduces the time and cost of drug development, offering a scalable model with blockbuster potential if a candidate reaches market.
Risks: No approved drugs yet, and clinical trial failures could tank the stock. High R&D costs may pressure profitability.
Recommended Allocation: 1-3% of a portfolio for aggressive investors.
Recursion uses AI to streamline drug discovery, analyzing vast biological datasets to identify promising compounds. Its platform has partnerships with major pharma companies like Roche and Bayer.
RXRX has been a volatile stock since its 2021 IPO, with a 25% average annual return but significant drawdowns during market corrections.
The global AI-driven drug discovery market is projected to grow at a 25% CAGR through 2030, and Recursion is a pioneer in this space.
Wild Card Investments: Alternative Opportunities
For investors willing to take on higher risks, alternative investments like crowdfunding and crypto-related biotech projects offer unique exposure to early-stage opportunities.
1. Crowdfunding Platforms (StartEngine, Wefunder)
Why Invest?: Early access to disruptive companies can yield significant rewards if they achieve IPO or acquisition.
Risks: Illiquidity (funds may be locked for years), high failure rates, and limited regulatory oversight increase risk.
Recommended Allocation: Cap at 2-5% of a portfolio to balance speculative upside with significant downside.
Platforms like StartEngine and Wefunder allow retail investors to back AI and biotech startups before they go public. Examples include companies developing AI-powered diagnostics or gene-editing therapies.
Successful startups can deliver 10x-100x returns, but the failure rate is high (~70% of startups fail within 5 years).
Investors can buy equity or convertible notes in private companies, typically with minimums as low as $100.
StartEngine has hosted campaigns for companies like Myriad Neuroscience (AI-driven mental health diagnostics) and Bioverge (biotech venture fund).
Watch Out: Biotech is R&D-heavy, so expect some duds. Spread your investments and avoid chasing hype around unproven startups.
Resources
👩🏽‍⚖️ Legal Stuff
Nothing in this newsletter is financial advice. Always do your own research and think for yourself.